Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib

Similar Items

• Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
  od: Janjigian, Yelena Y., i dr.
  Izdano: (2011)
• Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design
  od: Chaft, Jamie E., i dr.
  Izdano: (2011)
• Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation
  od: Oxnard, Geoffrey R., i dr.
  Izdano: (2010)
• Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
  od: Johnson, Melissa L., i dr.
  Izdano: (2011)
• EGFR exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib
  od: Naidoo, J, i dr.
  Izdano: (2015)